RxDoctor Payments Data

Dubert Guerrero, MD

Internal Medicine · Independence, MONPI 1811103989

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $262 of the $356 with a category attached, or 73.6%. It is spread thinly across 11 manufacturers, the largest accounting for just 22.8%. 2025 is the largest year on record at $166, more than ten times the $13 reported in 2019.

$356in general payments, 2019–2025

Across 20 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$81
  • Merck$76
  • Novo Nordisk$53
  • Astellas Pharma US Inc$23
  • Vertex$21
  • Lilly USA, LLC$19
  • plus $82 from 5 others
$368,607in research payments, 2019–2025

Across 15 payments — averaging $24,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$234K
  • Sanofi Pasteur Inc.$135K

What the payments were for

  • Food & beverage$26274%
  • Education$9426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$356 in reported general payments places this provider in the 55th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$27,489
Medicare patients
126
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi22$82,951
BiktarvyBictegrav/Emtricit/Tenofov Ala20$73,975
CeftriaxoneCeftriaxone Sodium15$3,864
Cefazolin Sodium23$633
Doxycycline Hyclate14$473
Cephalexin27$309
Atorvastatin Calcium16$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$16$82,95122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →